Emerging issues in public health genomics

Annual Review of Genomics and Human Genetics

Volumn 15, Issue , 2014, Pages 461-480

  Roberts, J Scott ^a   Dolinoy, Dana C ^a   Tarini, Beth A ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

bioethics; epigenetics; epigenomics; health education; newborn screening

Indexed keywords

DIETHYLSTILBESTROL; DNA;

ADULTHOOD; CHILDHOOD DISEASE; CLINICAL RESEARCH; DIET THERAPY; DNA MODIFICATION; DRUG EXPOSURE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE SEQUENCE; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOME; GENOMICS; HEALTH BEHAVIOR; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH HAZARD; HEALTH PRACTITIONER; HEALTH PROGRAM; HUMAN; MEDICAL ETHICS; MEDICOLEGAL ASPECT; NEWBORN SCREENING; NEXT GENERATION SEQUENCING; NONHUMAN; PHENYLKETONURIA; POPULATION GENETICS; PUBLIC HEALTH; REVIEW; RISK FACTOR; SOCIAL JUSTICE; SOCIOLOGY; TANDEM MASS SPECTROMETRY; UNITED STATES; VULNERABLE POPULATION; ETHICS; HIGH THROUGHPUT SEQUENCING; LEGISLATION AND JURISPRUDENCE; NEWBORN;

EPIGENOMICS; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PUBLIC HEALTH;

EID: 84906847369     PISSN: 15278204     EISSN: 1545293X     Source Type: Book Series    
DOI: 10.1146/annurev-genom-090413-025514     Document Type: Review

References (140)

1. Alexander D, van Dyck PC. 2006. A vision of the future of newborn screening. Pediatrics 117:S350-54
2. Am. Board Genet. Couns. 2014. Home page. http://www.abgc.net
3. Am. Coll. Med. Genet. 2008. ACMG statement on direct-to-consumer genetic testing. Policy Statement, Am. Coll. Med. Genet., Bethesda, MD. https://www.acmg.net/docs/ACMG-Statement-on-DTC-4.07.08.pdf
4. Am. Coll. Med. Genet. Genomics. 2014. ACMG updates recommendation on "opt out" for genome sequencing return of results. News Release, Apr. 1, Am. Coll. Med. Genet. Genomics, Bethesda, MD. https://www.acmg.net/docs/ Release-ACMGUpdatesRecommendations-final.pdf
5. Am. Soc. Hum. Genet. Board Dir., Am. Coll. Med. Genet. Board Dir. 1995. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am. J. Hum. Genet. 57:1233-41
6. Anderson OS, Sant KE, Dolinoy DC. 2012. Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J. Nutr. Biochem. 23:853-59
7. Barker DJP, Eriksson JG, Forsén T, Osmond C. 2002. Fetal origins of adult disease: strength of effects and biological basis. Int. J. Epidemiol. 31:1235-39
8. Barouki R, Gluckman PD, Grandjean P, Hanson M, Heindel JJ. 2012. Developmental origins of non-communicable disease: implications for research and public health. Environ. Health 11:42-51
9. Bekdash RA, Zhang C, Sarkar DK. 2013. Gestational choline supplementation normalized fetal alcohol-induced alterations in histone modifications, DNA methylation, and proopiomelanocortin (POMC) gene expression in β-endorphin-producing POMC neurons of the hypothalamus. Alcohol. Clin. Exp. Res. 37:1133-42
10. Berry SA, Brown C, Grant M, Greene CL, Jurecki E, et al. 2013. Newborn screening 50 years later: access issues faced by adults with PKU. Genet. Med. 15:591-99
11. Bollati V, Baccarelli A. 2010. Environmental epigenetics. Heredity 105:105-12
12. Bombard Y, Veenstra G, Friedman JM, Creighton S, Currie L, et al. 2009. Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ 338:b2175
13. Botkin JR, Goldenberg AJ, Rothwell E, Anderson RA, Lewis MH. 2013. Retention and research use of residual newborn screening bloodspots. Pediatrics 131:120-27
14. Burke W, Khoury M, Stewart A, Zimmern R. 2006. The path from genome-based research to population health: development of an international public health genomics network. Genet. Med. 8:451-58
15. Burke W, Matheny Antommaria AH, Bennett R, Botkin J, Clayton EW, et al. 2013. Recommendations for returning genomic incidental findings? We need to talk! Genet. Med. 15:854-59
16. Bustamante CD, Burchard EG, De La Vega FM. 2011. Genomics for the world. Nature 475:163-65
17. Camp KM, Lloyd-Puryear MA, Huntington KL. 2012. Nutritional treatment for inborn errors of metabolism: indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example. Mol. Genet. Metab. 107:3-9
18. Cent. Dis. Control Prev. 2012. CDC grand rounds: newborn screening and improved outcomes. Morb. Mortal. Wkly. Rep. 61:390-93
19. Cent. Dis. Control Prev. 2013. Pediatric genetics: newborn screening. http://www.cdc.gov/ncbddd/pediatricgenetics/newborn-screening.html
20. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. 2008. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Dis. Assoc. Disord. 22:94-97
21. Collotta M, Bertazzi PA, Bollati V. 2013. Epigenetics and pesticides. Toxicology 307:35-41
22. Comeau AM, Accurso FJ, White TB, Campbell PW, Hoffman G, et al. 2007. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 119:e495-518
23. Comm. Genet. 2008. Maternal phenylketonuria. Pediatrics 122:445-49
24. Cortessis VK, Thomas DC, Levine AJ, Breton CV, Mack TM, et al. 2012. Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships. Hum. Genet. 131:1565-89
25. Crews KR, Hicks JK, Pui C-H, Relling MV, Evans WE. 2012. Pharmacogenomics and individualized medicine: translating science into practice. Clin. Pharmacol. Ther. 92:467-75
26. Davis DS. 1997. Genetic dilemmas and the child's right to an open future. Hastings Cent. Rep. 27:7-15
27. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al. 2011. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43:491-98
28. Dolinoy DC, Faulk C. 2012. Introduction: the use of animals models to advance epigenetic science. ILAR J. 53:227-31
29. Dolinoy DC, Huang D, Jirtle RL. 2007. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc. Natl. Acad. Sci. USA 104:13056-61
30. vy mouse offspring from obesity by modifying the fetal epigenome. Environ. Health Perspect. 114:567-72
31. vy metastable epiallele. Epigenetics 5:637-44
32. Eur. Soc. Hum.Genet. 2009. Genetictesting in asymptomatic minors: recommendations of the European Society of Human Genetics. Eur. J. Hum. Genet. 17:238-51
33. Evans JP, Meslin EM, Marteau TM, Caulfield T. 2011. Deflating the genomic bubble. Science 331:861-62
34. Faulk C, Dolinoy DC. 2011. Timing is everything: the when and how of environmentally induced changes in the epigenome of animals. Epigenetics 6:791-97
35. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, et al. 2005. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. USA 102:10604-9
36. Genet. Alliance. 2013. Baby's First Test: conditions screened by state. http://www.babysfirsttest.org/newborn-screening/states
37. Geronimus AT. 2013. Deep integration: letting the epigenome out of the bottle without losing sight of the structural origins of population health. Am. J. Public Health 103:S56-63
38. Gigerenzer G, Edwards A. 2003. Simple tools for understanding risks: from innumeracy to insight. BMJ 327:741-44
39. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. 2008. Effect of in utero and early-life conditions on adult health and disease. N. Engl. J. Med. 359:61-73
40. Goldenberg AJ, Sharp RR. 2012. The ethical hazards and programmatic challenges of genomic newborn screening. JAMA 307:461-62
41. Gostin LO. 2000. Public Health Law: Power, Duty, Restraint. Berkeley: Univ. Calif. Press
42. Gostin LO, Powers M. 2006. What does social justice require for the public's health? Public health ethics and policy imperatives. Health Aff. 25:1053-60
43. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, et al. 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15:565-74
44. Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS. 2006. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics 117:923-29
45. Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ. 2010. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics 13:106-15
46. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. 2006. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics 117:1915-21
47. Gutierrez A. 2013. 23andMe, Inc. 11/22/13. Warn. Lett., US Food Drug Admin., Silver Spring, MD.
48. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ ucm376296.htm
49. Guttmacher AE, Jenkins J, Uhlmann WR. 2001. Genomic medicine: Who will practice it? A call to open arms. Am. J. Med. Genet. 106:216-22
50. Hajkova P, Erhardt S, Lane N, Haaf T, El-Maarri O, et al. 2002. Epigenetic reprogramming in mouse primordial germ cells. Mech. Dev. 117:15-23
51. Health Resour. Serv. Adm. 2013. Discretionary Advisory Committee on Heritable Disorders in Newborns and Children. http://www.hrsa.gov/ advisorycommittees/mchbadvisory/heritabledisorders
52. Hinton CF, Feuchtbaum L, Kus CA, Kemper AR, Berry SA, et al. 2011. What questions should newborn screening long-term follow-up be able to answer? A statement of the US Secretary for Health and Human Services' Advisory Committee onHeritable DisordersinNewborns and Children.Genet. Med. 13:861-65
53. Hoff T, Ayoob M, Therrell BL. 2007. Long-term follow-up data collection and use in state newborn screening programs. Arch. Pediatr. Adolesc. Med. 161:994-1000
54. Hoff T, Hoyt A, Therrell B, Ayoob M. 2006. Exploring barriers to long-term follow-up in newborn screening programs. Genet. Med. 8:563-70
55. Holliday R, Pugh JE. 1975. DNA modification mechanisms and gene activity during development. Science 187:226-32
56. Hudson K, Javitt G, Burke W, Byers P. 2007. ASHG statement on direct-to-consumer genetic testing in the United States. Obstet. Gynecol. 110:1392-95
57. Inst. Med. 2004. Health literacy: a prescription to end confusion. Rep., Natl. Acad. Sci., Washington, DC
58. Jiménez-Díaz I, Zafra-Gómez A, Ballesteros O, Navea N, Navalón A, et al. 2010. Determination of bisphenol A and its chlorinated derivatives in placental tissue samples by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 878:3363-69
59. Jirtle RL, Skinner MK. 2007. Environmental epigenomics and disease susceptibility. Nat. Rev. Genet. 8:253-62
60. Kemper AR, Hwu W-L, Lloyd-Puryear M, Kishnani PS. 2007. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics 120:e1327-34
61. King E, Shih G, Ratnapradipa D, Quilliam DN, Morton J, Magee SR. 2013. Mercury, lead, and cadmium in umbilical cord blood. J. Environ. Health 75:38-43
62. Kohane IS, Masys DR, Altman RB. 2006. The incidentalome: a threat to genomic medicine. JAMA 296:212-15
63. Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC. 2011. Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet. Test. Mol. Biomark. 15:871-75
64. Korobkin R, Rajkumar R. 2008. The Genetic Information Nondiscrimination Act-a half-step toward risk sharing. N. Engl. J. Med. 359:335-37
65. Krueger C, Horesh E, Crossland BA. 2012. Safe sound exposure in the fetus and preterm infant. J. Obstet. Gynecol. Neonatal Nurs. 41:166-70
66. Kwon JM, Steiner RD. 2011. "I'm fine; I'm just waiting for my disease": the new and growing class of presymptomatic patients. Neurology 77:522-23
67. Laird PW. 2010. Principles and challenges of genomewide DNA methylation analysis. Nat. Rev. Genet. 11:191-203
68. Lewis MH, Goldenberg A, Anderson R, Rothwell E, Botkin J. 2011. State laws regarding the retention and use of residual newborn screening blood samples. Pediatrics 127:703-12
69. Lipkus IM. 2007. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med. Decis. Making 27:696-713
70. Lloyd-Puryear MA, Tonniges T, van Dyck PC, Mann MY, Brin A, et al. 2006. American Academy of Pediatrics Newborn Screening Task Force recommendations: How far have we come? Pediatrics 117:S194-211
71. Macleod EL, Ney DM. 2010. Nutritional management of phenylketonuria. Ann. Nestlé Engl. 68:58-69
72. Mandl KD, Feit S, Larson C, Kohane IS. 2002. Newborn screening program practices in the United States: notification, research, and consent. Pediatrics 109:269-73
73. Manikkam M, Guerrero-Bosagna C, Tracey R, Haque MM, Skinner MK. 2012. Transgenerational actions of environmental compounds on reproductive disease and identification of epigenetic biomarkers of ancestral exposures. PLoS ONE 7:e31901
74. Marchini J, Howie B. 2010. Genotype imputation for genome-wide association studies. Nat. Rev. Genet. 11:499-511
75. Marteau T, Senior V, Humphries SE, Bobrow M, Cranston T, et al. 2004. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am. J. Med. Genet. A 128A:285-93
76. Martinez-Arguelles DB, Campioli E, Culty M, Zirkin BR, Papadopoulos V. 2013. Fetal origin of endocrine dysfunction in the adult: the phthalate model. J. Steroid Biochem. Mol. Biol. 137:5-17
77. McBride CM, Koehly LM, Sanderson SC, Kaphingst KA. 2010. The behavioral response to personalized genetic information: Will genetic risk profiles motivate individuals and families to choose more healthful behaviors? Annu. Rev. Public Health 31:89-103
78. McCandless SE, Chandrasekar R, Linard S, Kikano S, Rice L. 2013. Sequencing from dried blood spots in infants with "false positive" newborn screen for MCAD deficiency. Mol. Genet. Metab. 108:51-55
79. McCann PJC. 2009. Agency discretion and public health service delivery. Health Serv. Res. 44:1897-908
80. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, et al. 2008. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9:356-69
81. McGuire AL, Burke W. 2008. An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 300:2669-71
82. Mikail CN. 2008. Public Health Genomics: The Essentials. San Francisco: Jossey-Bass
83. Mirnezami R, Nicholson J, Darzi A. 2012. Preparing for precision medicine. N. Engl. J. Med. 366:489-91
84. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, et al. 2013. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet. Genomics 23:383-94
85. Moyer VA, Calonge N, Teutsch SM, Botkin JR. 2008. Expanding newborn screening: process, policy, and priorities. Hastings Cent. Rep. 38:32-39
86. Murrell A, Rakyan VK, Beck S. 2005. From genome to epigenome. Hum. Mol. Genet. 14:R3-R10
87. Nahar MS, Liao C, Kannan K, Dolinoy DC. 2013. Fetal liver bisphenol A concentrations and biotransformation gene expression reveal variable exposure and altered capacity for metabolism in humans. J. Biochem. Mol. Toxicol. 27:116-23
88. Natl. Hum. Genome Res. Inst. 2014. Clinical Sequencing Exploratory Research (CSER). Updated Apr. 1.
89. http://www.genome.gov/27546194
90. Natl. Inst. Health. 2013. NIH program explores the use of genomic sequencing in newborn healthcare. News Release, Sept. 4, Natl. Inst. Health, Bethesda, MD. http://www.nih.gov/news/health/sep2013/nhgri-04.htm
91. Natl. Newborn Screen. Genet. Resour. Cent. 2003. National newborn screening report-2000. Rep., Natl. Newborn Screen. Genet. Resour. Cent., Austin, TX. http://genes-r-us.uthscsa.edu/sites/genes-r-us/files/resources/newborn/00/ 2000Report.pdf
92. Natl. Soc. Genet. Couns. 2013. What is genetic counseling? http://nsgc.org/p/cm/ld/fid=43
93. Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, et al. 2012. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ. 21:238-51
94. Neumann PJ, Hammitt JK, Mueller C, Fillit HM, Hill J, et al. 2001. Public attitudes about genetic testing for Alzheimer's disease. Health Aff. 20:252-64
95. Newbold RR. 2004. Lessons learned from perinatal exposure to diethylstilbestrol. Toxicol. Appl. Pharmacol. 199:142-50
96. Newborn Screen. Authoring Comm. 2008. Newborn screening expands: recommendations for pediatricians and medical homes-implications for the system. Pediatrics 121:192-217
97. Nguyen CP, Goodman LH. 2012. Fetal risk in diagnostic radiology. Semin. Ultrasound CT MRI 33:4-10
98. Nielsen R, Paul JS, Albrechtsen A, Song YS. 2011. Genotype and SNP calling from next-generation sequencing data. Nat. Rev. Genet. 12:443-51
99. Nilsson E, Larsen G, Manikkam M, Guerrero-Bosagna C, Savenkova MI, Skinner MK. 2012. Environmentally induced epigenetic transgenerational inheritance of ovarian disease. PLoS ONE 7:e36129
100. Petronis A. 2006. Epigenetics and twins: three variations on the theme. Trends Genet. 22:347-50
101. Phelan JC, Yang LH, Cruz-Rojas R. 2006. Effects of attributing serious mental illnesses to genetic causes on orientations to treatment. Psychiatr. Serv. 57:382-87
102. Platt LD, Koch R, Hanley WB, Levy HL, Matalon R, et al. 2000. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. Am. J. Obstet. Gynecol. 182:326-33
103. Pres. Counc. Bioeth. 2008. The changing moral focus of newborn screening: an ethical analysis by the President's Council on Bioethics. Rep., Pres. Counc. Bioeth., Washington, DC. https://bioethicsarchive. georgetown.edu/pcbe/reports/ newborn-screening
104. Ravitsky V, Wilfond BS. 2006. Disclosing individual genetic results to research participants. Am. J. Bioeth. 6:8-17
105. Roberts JS, LaRusse SA, Katzen H, Whitehouse PJ, Barber M, et al. 2003. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 17:86-93
106. Roberts JS, Ostergren J. 2013. Direct-to-consumer genetic testing and personal genomics services: a review of recent empirical studies. Curr. Genet. Med. Rep. 1:182-200
107. Rothstein MA. 2013. Epigenetic exceptionalism. J. Law Med. Ethics 41:733-36
108. Roychowdhury S, Chinnaiyan AM. 2013. Advancing precision medicine for prostate cancer through genomics. J. Clin. Oncol. 31:1866-73
109. Sankar P, Cho MK, Condit CM, Hunt LM, Koenig B, et al. 2004. Genetic research and health disparities. JAMA 291:2985-89
110. Senior V, Marteau TM. 2007. Causal attributions for raised cholesterol and perceptions of effective risk-reduction: self-regulation strategies for an increased risk of coronary heart disease. Psychol. Health 22:699-717
111. Shalowitz DI, Miller FG. 2008. Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med. 5:e91
112. Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, et al. 2007. Genome-wide profiling of DNA methylation reveals a class of normally methylated CPG island promoters. PLoS Genet. 3:2023-36
113. Singleton A, Erby LH, Foisie KV, Kaphingst KA. 2012. Informed choice in direct-to-consumer genetic testing (DTCGT) websites: a content analysis of benefits, risks, and limitations. J. Genet. Couns. 21:433-39
114. Skinner MK, Manikkam M, Guerrero-Bosagna C. 2011. Epigenetic transgenerational actions of endocrine disruptors. Reprod. Toxicol. 31:337-43
115. Solomon BD, Pineda-Alvarez DE, Bear KA, Mullikin JC, Evans JP. 2012. Applying genomic analysis to newborn screening. Mol. Syndromol. 3:59-67
116. Stoddard JJ, Farrell PM. 1997. State-to-state variations in newborn screening policies. Arch. Pediatr. Adolesc. Med. 151:561-64
117. Tarini BA. 2011. Storage and use of residual newborn screening blood spots: a public policy emergency. Genet. Med. 13:619-20
118. Tarini BA, Christakis DA, Welch HG. 2006. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results. Pediatrics 118:448-56
119. Tarini BA, Goldenberg AJ. 2012. Ethical issues with newborn screening in the genomics era. Annu. Rev. Genomics Hum. Genet. 13:381-93
120. Taylor DH, Cook-Deegan RM, Hiraki S, Roberts JS, Blazer DG, Green RC. 2010. Genetic testing for Alzheimer's and long-term care insurance. Health Aff. 29:102-8
121. Teschendorff AE, West J, Beck S. 2013. Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Hum. Mol. Genet. 22:R7-R15
122. Timmermans S, Buchbinder M. 2010. Patients-in-waiting: living between sickness and health in the genomics era. J. Health Soc. Behav. 51:408-23
123. Tluczek A, Koscik RL, Farrell PM, Rock MJ. 2005. Psychosocial risk associated with newborn screening for cystic fibrosis: parents' experience while awaiting the sweat-test appointment. Pediatrics 115:1692-703
124. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR, et al. 2012. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr. Rev. 33:378-455
125. Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC. 2010. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am. J. Clin. Nutr. 91:1402-7
126. Waddington CH. 1940. Organisers and Genes. Cambridge, UK: Cambridge Univ. Press
127. Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, et al. 2003. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290:2564-72
128. Waterland RA, Jirtle RL. 2003. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol. Cell. Biol. 23:5293-300
129. Wei C, Lu Q, Khoo SK, Lenski M, Fichorova RN, et al. 2014. Comparison of frozen and unfrozen blood spots for gene expression studies. J. Pediatr. 164:189-91
130. Wenzel A, Gorman LL, O'Hara MW, Stuart S. 2001. The occurrence of panic and obsessive compulsive symptoms in women with postpartum dysphoria: a prospective study. Arch. Women's Ment. Health 4:5-12
131. Wenzel A, Haugen EN, Jackson LC, Brendle JR. 2005. Anxiety symptoms and disorders at eight weeks postpartum. J. Anxiety Disord. 19:295-311
132. Wenzel A, Haugen EN, Jackson LC, Robinson K. 2003. Prevalence of generalized anxiety at eight weeks postpartum. Arch. Women's Ment. Health 6:43-49
133. Wetterstrand KA. 2014. DNA sequencing costs: data from the NHGRI Genome Sequencing Program (GSP). Updated Apr. 8. http://www.genome.gov/sequencingcosts
134. Wigle DT, Arbuckle TE, Walker M, Wade MG, Liu S, Krewski D. 2007. Environmental hazards: evidence for effects on child health. J. Toxicol. Environ. Health B 10:3-39
135. Wilfond B, Ross LF. 2009. From genetics to genomics: ethics, policy, and parental decision-making. J. Pediatr. Psychol. 34:639-47
136. Wilson JMG, Jungner G. 1968. Principles and Practice of Screening for Disease. Geneva: World Health Organ.
137. Wolf SM, Crock BN, Van Ness B, Lawrenz F, Kahn JP, et al. 2012. Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet. Med. 14:361-84
138. Woloshin S, Schwartz LM, Welch HG. 2008. Know Your Chances: Understanding Health Statistics. Berkeley: Univ. Calif. Press
139. Youngson NA, Whitelaw E. 2008. Transgenerational epigenetic effects. Annu. Rev. Genomics Hum. Genet. 9:233-57
140. Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC. 2005. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff. 24:483-90